hims ozempic - Search News

Hims & Hers, Novo Nordisk

Hosted on MSN · 1d

Stock of the Day: Hims & Hers plunges 27% after saying it will stop selling its Ozempic competitor

With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared "aspirational."

MarketWatch on MSN · 1d

Novo Nordisk shares are rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.

Wall Street Journal · 1d

Novo Nordisk Stock Rises on Weight-Loss Retreat by Hims & Hers

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to Novo Nordisk's Wegovy and Ozempic weight-loss drugs. Hims stock stood about 17% lower at under $42.

Hims & Hers, Drug and compounding

Quartz on MSN · 1d

Hims & Hers can't sell off-brand Ozempic forever. But it can still sell these weight loss drugs

Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, the company will soon have to halt sales of its cheaper alternative. That said,

Hims & Hers tumbles 27% as investors fear uncertainty without compounded weight-loss drugs

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

The Hill on MSN · 1d

Drug compounders sue over weight loss drugs’ removal from FDA shortage list

A trade group representing compounding pharmacies has filed a lawsuit against the Food and Drug Administration (FDA) for removing semaglutide, the active ingredient in Ozempic, from its drug shortage list.

1don MSN

Hims is officially phasing out its copycat weight-loss drugs, and the company's stock tumbled — again

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

ConsumerAffairs1d

Hims & Hers withdraws from Wegovy, Ozempic market

Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...

Hims and Hers likely to stop selling cheaper versions of GLP-1 medications

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

5don MSN

Hims & Hers Stock Drops as FDA Says Ozempic and Wegovy No Longer in Short Supply

Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...

3don MSN

Wegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers

The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.

HIMS Stock Craters - Is It a Buying Opportunity?

Shares of Hims & Hers Health (NASDAQ:HIMS) continued to meltdown Tuesday in noontime trading after the direct-to-consumer ...

7h

Hims & Hers: Brace For Impact As It Faces A Possible 18% Revenue Hit

Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...

1don MSN

Hims & Hers Health, Inc.: Jim Cramer Warns ‘The Gravy Train Might Be Over’ After FDA’s Ozempic Update

We recently published a list of Jim Cramer on 10 Stocks With The Biggest Declines Last Week. In this article, we are going to ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results